aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
September 15, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
September 14, 2020 08:03 ET
|
aTyr Pharma, Inc.
Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months. SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a...
aTyr Pharma to Present at September Investor Conferences
September 09, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs
August 13, 2020 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan
August 11, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
August 06, 2020 08:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
June 22, 2020 08:00 ET
|
aTyr Pharma, Inc.
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN...
aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection
June 17, 2020 17:00 ET
|
aTyr Pharma, Inc.
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory...
aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
June 15, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 20, 2020 08:03 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...